This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Tuesday's Health Winners & Losers

Mergers, earnings and an IPO jolted a few biotech stocks Tuesday.

Medical device company E-Z-EM (EZEM) said Tuesday that it agreed to be bought by Bracco Diagnostics for $241 million, or $21 a share, pending shareholder vote. The price is a 32% premium over the 10-day average closing price as of Oct. 29.

Shares rose $4.08, or 24.9%, to $20.50.

Nycomed also said it will buy dermatologic company Bradley Pharmaceuticals (BDY) for $346 million. The bid is for $20 a share, a $4 premium over Monday's closing price of $16. Bradley's board approved the merger, which is now subject to shareholder vote. Shares added $3.80, or 23.8%, to $19.80.

On the earnings front, Sepracor (SEPR) reported a third-quarter profit of $42.9 million, or 37 cents a share, compared to $64.4 million, or 56 cents a share, a year ago. It reported revenue of $283.9 million, a 1.9% decrease from $289.3 million in the year-ago quarter. Analysts surveyed by Thomson Financial had expected 26 cents a share on revenue of $289 million.

The company also said it will cut 300 jobs, resulting in a reduction in sales and marketing expenses of $90 million to $100 million. Shares climbed $3.88, or 16.9%, to $26.90.

Teva Pharmaceuticals (TEVA) reported third-quarter earnings of $525 million, or 64 cents a share, vs. a profit of $606 million, or 74 cents a share, in the year-ago quarter. Revenue rose to $2.37 billion from $2.29 billion in 2006. Analysts polled by Thomson Financial expected profit of 63 cents per share on revenue of $2.41 billion.

The company also said CFO Dan Suesskind, who worked at the company for 31 years, will retire in the middle of next year. He'll be replaced by Eyal Desheh, chief financial officer of Check Point Software Technologies in Tel Aviv. Teva shares gave up 83 cents, or 1.9% to $43.66.

Teva is a component of the Amex Pharmaceutical Index, which edged lower 0.05, or 0.01%, to 348.66.

Monday after close, Nastech (NSTK) reported a loss of $16.5 million, or 66 cents a share, vs. a loss of $7.8 million, or 36 cents a share, in the year-ago quarter. Revenue fell 66 percent to $1.9 million from $5.5 million in the year-earlier period. Analysts polled by Thomson Financial expected a loss of 44 cents a share. Shares fell $1.80, or 12.1%, to $13.05.

Viropharm (VPHM) said it earned $21.3 million, or 26 cents a share, vs. $23.3 million, or 33 cents a share, in the comparable 2006 quarter. Revenue fell to $50.9 million from $55.2 million. Analysts surveyed by Thomson Financial had expected 27 cents a share, on revenue of $52 million.

Shares fell 67 cents, or 7.2%, to $8.77.

Elsewhere, Genoptix (GXDX) soared 56.4% after its IPO, which priced 5 million shares at $17 a pop, along with a 750,000-share underwriters' option. Shares of the San Diego-based diagnostic services provider were up $9.59 to $26.59.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,786.60 +8.45 0.05%
S&P 500 2,064.91 +3.68 0.18%
NASDAQ 4,757.8120 +9.4160 0.20%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs